A lack of female participants in clinical trials and a failure to report separate results by gender could lead to drugs being marketed that are less effective for women, a study has warned. Jeanine Roeters van Lennep at Jeanine Roeters van Lennep 's the Erasmus Medical Centre said the absence of women in clinical trials was a "blind spot", while an analysis of 45 UK statins trials revealed 82% of the participants were men, and 10 separated data by the sex of participants. “Women are not small men,” said Jeanine Roeters van Lennep, of the Erasmus Medical Centre in Rotterdam, who is leading the project. Separate UK research found that 45 out of 10 drugs withdrawn from use after approval had higher risks for women.
A lack of female participants in clinical trials and a failure to report separate results by gender could lead to drugs being marketed that are less effective for women, a study has warned. Jeanine Roeters van Lennep at Jeanine Roeters van Lennep 's the Erasmus Medical Centre said the absence of women in clinical trials was a "blind spot", while an analysis of 45 UK statins trials revealed 82% of the participants were men, and 10 separated data by the sex of participants. Separate UK research found that 45 out of 10 drugs withdrawn from use after approval had higher risks for women.